TOSHIBA
27.8.2020 07:02:11 CEST | Business Wire | Press release
Toshiba Electronic Devices & Storage Corporation (“Toshiba”) has launched three photorelays: “TLP3407SRA ,” “TLP3475SRHA ” and “TLP3412SRHA ,” that are the industry-smallest[1] voltage driven photorelays with an extended operating temperature rating of 125°C.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200826005815/en/
Raising the maximum operating temperature rating from 110°C to 125°C allows the photorelays to be mounted in high temperature areas, and makes it easier to secure required temperature design margins for equipment. The S-VSON4T package has the industry-smallest[1] mounting area of 2.9mm² .This will contribute to reducing PCB size or to increasing the number of photorelays in an existing layout in applications such as semiconductor testers, probe cards and other devices.
Applications
- Semiconductor testers (memory, SoC and LSI, etc.)
- Probe cards
- Burn-in equipment
- Measuring instruments (oscilloscope, data logger, etc.)
Features
- S-VSON4T, the industry’s first[1] packaging with a minimal mounting area and maximum operating temperature of 125°C: Mounting area 2.9mm2 (typ.)
- Low input power consumption drive: 3.3mW[2] (max) @VIN =3.3V (TLP3407SRA)
Main Specifications
(＠Ta =25℃) |
||||
Part number |
||||
Package |
Name |
S-VSON4T |
||
Size typ. (mm) |
2.0×1.45 |
|||
Height typ.(mm) |
1.3 |
|||
Recommended
|
Applied input forward voltage VIN typ. (V) |
3.3 |
3.3 |
3.3 |
Built-in resistance typ. (Ω) |
4000 |
600 |
600 |
|
Absolute maximum ratings |
OFF-state output terminal voltage VOFF (V) |
60 |
60 |
60 |
ON-state current ION (A) |
1 |
0.4 |
0.4 |
|
ON-state current (pulsed) IONP (A) |
3 |
1.2 |
1.2 |
|
Operating temperature Topr (℃) |
-40 to 125 |
|||
Coupled
|
Limited LED current ILIM(LED) max (mA) (@VIN ) |
1
|
- |
- |
Trigger LED current IFT max (mA) |
0.2 |
2 |
2 |
|
Operating voltage VFON max (V) |
3 |
3 |
3 |
|
ON-state resistance RON max (Ω) |
0.3 |
1.5 |
1.5 |
|
Electrical characteristics |
Output capacitance COFF typ. (pF) |
80 |
12 |
20 (max) |
OFF-state current IOFF max (nA) (@VOFF ) |
1 (@50V) |
1 (@50V) |
1 (@50V) |
|
Switching characteristics |
Turn-on time tON max (ms) |
20 |
0.5 |
0.5 |
Turn-off time tOFF max (ms) |
1 |
0.2 |
0.2 |
|
Isolation characteristic |
Isolation voltage BVS min (Vrms) |
500 |
500 |
500 |
Sample Check & Availability |
||||
Notes:
[1] For photorelays where maximum operating temperature rating is 125°C, according to a survey by Toshiba (as of August 25, 2020).
[2] Applied input forward voltage × maximum limited LED current=3.3V×1mA
Follow the link below for more on the new photocouplers.
TLP3407SRA
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TLP3407SRA
TLP3475SRHA
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TLP3475SRHA
TLP3412SRHA
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TLP3412SRHA
Follow the link below for more on Toshiba’s photorelay lineup.
https://toshiba.semicon-storage.com/ap-en/semiconductor/product/optoelectronics/photorelay-mosfet-output.html
To check availability of the new products at online distributors, visit:
TLP3407SRA
https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TLP3407SRA.html
TLP3475SRHA
https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TLP3475SRHA.html
TLP3412SRHA
https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TLP3412SRHA.html
Customer Inquiries:
Optoelectronic Device Sales & Marketing Dept.
Tel: +81-3-3457-3431
https://toshiba.semicon-storage.com/ap-en/contact.html
* Company names, product names, and service names may be trademarks of their respective companies.
* Information in this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but is subject to change without prior notice.
About Toshiba Electronic Devices & Storage Corporation
Toshiba Electronic Devices & Storage Corporation combines the vigor of a new company with the wisdom of experience. Since becoming an independent company in July 2017, the company has taken its place among the leading general devices companies, and offers its customers and business partners outstanding solutions in discrete semiconductors, system LSIs and HDD.
Its 24,000 employees around the world share a determination to maximize the value of its products, and emphasize close collaboration with customers to promote co-creation of value and new markets. The company looks forward to building on annual sales now surpassing 750-billion yen (US$6.8 billion) and to contributing to a better future for people everywhere.
Find out more about Toshiba Electronic Devices & Storage Corporation at https://toshiba.semicon-storage.com/ap-en/top.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20200826005815/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom